Granulocyte colony stimulating factor (G-CSF)

DRUG2 trials

Sponsors

EMD Serono Research & Development Institute, Inc., Massachusetts General Hospital

Conditions

Advanced Solid TumorGlioblastoma (GBM)MGMT-Methylated GlioblastomaNewly Diagnosed Glioblastoma Multiforme

Phase 1

M9466 in Combination With Topoisomerase 1 Inhibitors-based Regimens in Advanced Solid Tumors and Colorectal Cancer (DDRiver 511)

TerminatedNCT06509906

EMD Serono Research & Development Institute, Inc.Advanced Solid Tumor

Start: 2024-10-08End: 2025-12-02Updated: 2025-12-18

Phase 2

G-CSF After Chemo-radiation in Patients With Glioblastoma

RecruitingNCT06649851

Massachusetts General HospitalGlioblastoma (GBM), MGMT-Methylated Glioblastoma, Newly Diagnosed Glioblastoma Multiforme

Start: 2025-04-02End: 2030-01-31Target: 60Updated: 2025-09-25

Related Papers

Abstract 1171: M9466 (HRS-1167): A highly potent and selective PARP1 inhibitor with DNA trapping activity, monotherapy antitumor activity and synergistic potential with DDR inhibitors and chemotherapies

Cancer Research2025-04-21